New QA tests Methods Speed Pharma Products to Production. Qualified Sales Reps are Needed

WASHINGTON - May 2, 2013 - PRLog -- It seems that most new proposals for improving public health and the nation's economy offer ways to reduce the cost and time of drug development and thus speed more new products to sales teams, doctors, and patients. This is particularly evident in the string of "pro-innovative" approaches for testing and regulating medical products proposed as add-ons to Food and Drug Administration (FDA) user fee legislation moving forward on Capitol Hill.

These new approaches allow companies to get their products to their sales teams quicker than usual, which means representatives are going to be moving at a faster pace. Training is key, and Certified National Pharmaceutical Representatives (CNPR) must have as much prior industry knowledge as possible in order to succeed.

Pharmaceutical companies will require their new hires to understand pharmacology, medical terminology, selling guidelines, understanding relevant disease areas and much more before they send them out into the field.

Typical of the broader look, the "Bioeconomy Blueprint" issued by the White House Office of Science and Technology Policy in April maps out how biotechnological advances can promote economic growth, create new jobs, and improve health. A strong undercurrent in this grab bag of ideas is that innovation will flourish by eliminating unnecessary regulatory roadblocks. Thus it supports revisions in rules governing human subject research and proposes to tap into FDA's vast repository of drug safety and efficacy data to speed drug development.

The initiative will start with the new National Center for Advancing Translational Sciences (NCATS) funding $20 million in grants next year to support promising research proposals, along with templates for agreements on dealing with intellectual property. The companies will provide researchers with the compounds and relevant data, while retaining rights to their products. Scientists from academia, non-profits, or biotech companies will be able to publish study results and negotiate licenses on new discoveries. The program intentionally ruled out seeking additional uses for approved drugs, as those raise more complex IP issues. NIH is soliciting comments on the templates, which are key to speeding up negotiations among all parties and making the program work. A list of compounds available for research will be published in a few months, and initial grants awarded next spring.

For more information on a career in pharmaceutical sales, contact the National Association of Pharmaceutical Representatives (NAPRx) at 800-284-1060.

www.napsronline.org